Search

The ViRNAExTM - Viral Extraction solution is designed for rapid (15 min) isolation of viral RNA and DNA (nucleic acids - NA) from nasopharyngeal swabs, buccal swabs, sputum and saliva using specially developed technology to remove inhibitors.

The isolation is designed for use on low nucleic acid samples. Isolated NA are suitable for amplification techniques such as RT-PCR of viral NA in clinical samples. 

Package contents: 10 mL (100 isolations).

The ViRNAExTM - Viral Extraction solution is designed for rapid (15 min) isolation of viral RNA and DNA (nucleic acids - NA) from nasopharyngeal swabs, buccal swabs, sputum and saliva using specially developed technology to remove inhibitors.

The isolation is designed for use on low nucleic acid samples. Isolated NA are suitable for amplification techniques such as RT-PCR of viral NA in clinical samples.

Package contents: 50 mL (500 isolations).

Rapid immunochromatographic test for the qualitative detection of SARS-CoV-2 Nucleocapsid Protein antigen in human nasopharyngeal swab samples as an aid in rapid diagnosis of Coronavirus (Covid-19) infection.

Test sensitivity: 97.3% (95% CI: 90.0% - 99.8%)

Test specificity: 100.0% (95% CI: 96.6% - 100%) 

Relative accuracy: 98.8% (95% CI: 91.8% - 99.9%)

* Confidence Intervals

Rapid immunochromatographic test for the qualitative detection of SARS-CoV-2 Nucleocapsid Protein antigen in human nasopharyngeal swab samples as an aid in rapid diagnosis of Coronavirus (Covid-19) infection.

Test sensitivity: 97.3% (95% CI: 90.0% - 99.8%)

Test specificity: 100.0% (95% CI: 96.6% - 100%) 

Relative accuracy: 98.8% (95% CI: 91.8% - 99.9%)

* Confidence Intervals

Rapid immunochromatographic test for the qualitative detection of SARS-CoV-2, Influenza A and Influenza B virus antigens in nasopharyngeal swab specimens from individuals with suspected SARS-CoV-2 / Influenza infection in conjunction with clinical presentation and the results of other laboratory tests.

SARS-CoV-2 Ag
Relative Sensitivity: 96.4% (95% CI*: 89.8% - 99.2%)

Relative Specificity: 99.2% (95% CI*: 95.5% - 99.9%)

Accuracy: 98.0% (95% CI*: 95.1% - 99.5%)
* Confidence Intervals

Influenza type A

Relative Sensitivity: 94.1% (95% CI*: 71.3% - 99.9%)

Relative Specificity: 98.4% (95% CI*: 91.5% - >99.9%)

Accuracy: 97.5% (95% CI*: 91.3% - 99.7%) 98.8%
* Confidence Intervals

Influenza type B
Relative Sensitivity: 91.7% (95% CI*: 61.5% - 99.8%)

Relative Specificity: 100.0% (95% CI*: 95.7% - 100.0%)

Accuracy: 98.8% (95% CI*: 93.2% - >99.9%)

* Confidence Intervals

Rapid immunochromatographic test for the qualitative detection of SARS-CoV-2 virus antigens in nasopharyngeal swab specimens as an aid in rapid diagnosis of Coronavirus (Covid-19) infection.

Relative Sensitivity: 96.4% (95% CI*: 89.8% - 99.2%)

Relative Specificity: 99.2% (95% CI*: 95.5% - 99.9%)

Accuracy: 98.0% (95% CI*: 95.1% - 99.5%)
* Confidence Intervals

The ViroQ SARS-FluA/B-RSV Kit is used for qualitative detection of SARS-CoV-2, Influenza A, Influenza B and RSV (Respiratory Syncytial Virus) RNA in the samples taken from the throat-nasal swab based on reverse transcription of the RNA and subsequent amplification in real-time PCR.

The ViroQ SARS-FluA/B-RSV Kit is used for qualitative detection of SARS-CoV-2, Influenza A, Influenza B and RSV (Respiratory Syncytial Virus) RNA in the samples taken from the throat-nasal swab based on reverse transcription of the RNA and subsequent amplification in real-time PCR.

The IDK® anti-SARS-CoV-2 IgG is an enzyme-linked immunosorbent assay (ELISA) for qualitative measurement of IgG antibodies against the novel coronavirus SARS-CoV-2 in human serum or EDTA plasma.

This ELISA can be performed manually or using an automated platform. This test serves as complement to infection diagnosis and provides evidence for a previous infection with SARS-CoV-2.

The MutaPLEX® Coronavirus (SARS-CoV-2) Real-Time-RT-PCR kit is a screening as-say for the simultaneous detection of RNA of novel coronavirus (SARS-CoV-2) and the Subgenus Sarbecovirus (SARS related Betacoronavirus: SARS-CoV-1 and SARS-CoV-2) extracted from biological specimens.

Rapid immunochromatographic test for the qualitative detection of SARS-CoV-2 antigens in oral fluid specimens from individuals with suspected SARS-CoV-2 infection in conjunction with clinical presentation and the results of other laboratory tests.

Relative sensitivity: 90.1% (95% CI*:82.5%~95.1%)

Relative specificity: 99.3% (95% CI*: 97.7%~99.9%)

Accuracy: 97.0% (95% CI*: 94.9%~98.5%)

*Confidence Intervals